Alto Neuroscience (NYSE: ANRO) has announced the appointment of industry veteran Raymond Sanchez, MD, to its board of directors (BOD), effective August 12, 2025.
Dr. Sanchez brings extensive experience in medicine and life sciences to the role, and has served as a senior advisor at Bain Capital Life Sciences since September 2024.
Amit Etkin, MD, PhD, founder and CEO of Alto, remarked, “We are delighted to welcome Ray to our BOD as we continue advancing multiple clinical-stage precision psychiatry programs. Ray brings an impressive track record in guiding the successful development of numerous CNS therapies, and his strategic insights will be instrumental as we prepare to initiate our potentially pivotal, Phase 2b trial of ALTO-207. Ray is a tremendous addition to our board, and we believe his dedication to improving patient outcomes through innovation in psychiatry bring important contributions to our mission.”
Dr. Sanchez added, “As a psychiatrist by training, I’ve witnessed firsthand the lack of innovation in the field, even as it remains one of the most urgent areas of unmet medical need. I’m thrilled to join Alto at such an exciting time as the company aims to redefine the standard of care by moving beyond the outdated trial-and-error approach that has long dominated CNS drug development and clinical practice. With a robust late-stage pipeline and a strategic vision rooted in biology-driven precision medicine, I look forward to supporting Alto’s mission to deliver novel therapeutic solutions to the patients who need them most.”
